Prostate-cancer mortality after PSA screening

New England Journal of Medicine

Volumn 366, Issue 23, 2012, Pages 2229-

  D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER SCREENING; HUMAN; LETTER; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZATION; SCREENING TEST; VALIDITY;

EARLY DETECTION OF CANCER; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84861847420     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Andriole GL, Crawford ED, Grubb RI III, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow up. J Natl Cancer Inst 2012;104:125-32.
2. Pinsky PF, Black A, Kramer BS, Miller A, Prorok P, Berg C. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials 2010;7:303-11.
3. Kerkhof M, Roobol ML, Cuzick J, et al. Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam). Int J Cancer 2010;127:2639-44.